Zacks Investment Research Downgrades Cytori Therapeutics (CYTX) to Hold

Cytori Therapeutics (NASDAQ:CYTX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company’s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. “

CYTX has been the topic of several other reports. ValuEngine upgraded shares of Cytori Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, July 2nd. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Cytori Therapeutics in a research report on Tuesday, September 18th. Finally, Maxim Group cut shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 15th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $10.56.

Shares of NASDAQ CYTX opened at $0.42 on Tuesday. The stock has a market cap of $3.13 million, a PE ratio of -0.06 and a beta of 2.52. Cytori Therapeutics has a 12-month low of $0.31 and a 12-month high of $5.50.

Cytori Therapeutics (NASDAQ:CYTX) last announced its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.09). The business had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $2.50 million. Cytori Therapeutics had a negative net margin of 380.64% and a negative return on equity of 202.09%. As a group, sell-side analysts anticipate that Cytori Therapeutics will post -0.85 earnings per share for the current fiscal year.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.

Further Reading: Cash Flow Analysis in Stock Selection

Get a free copy of the Zacks research report on Cytori Therapeutics (CYTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply